Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial

被引:75
作者
Salim, A. [1 ]
Tan, E. [1 ]
Ilchyshyn, A. [1 ]
Berth-Jones, J. [1 ]
机构
[1] Univ Hosp Coventry & Warwickshire NHS Trust, Walsgrave Hosp, Dept Dermatol, Coventry CV2 2DX, W Midlands, England
关键词
Dermatology Life Quality Index; folate; methotrexate; psoriasis; Psoriasis Area and Severity Index; randomized controlled trial;
D O I
10.1111/j.1365-2133.2006.07289.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The value of folate supplementation in methotrexate (MTX)-treated patients remains controversial. To determine the effect of folic acid (FA) on the efficacy of MTX and the frequency of side-effects associated with MTX therapy. A 12-week double-blind clinical trial was conducted in patients with psoriasis stable on their long-term MTX doses but not receiving FA. They were randomized into two arms of either FA 5 mg or placebo daily. MTX doses were not changed throughout the study. Patients were monitored every 3 weeks by the same observer. Assessments included Psoriasis Area and Severity Index (PASI), a visual analogue scale (VAS) of patients' perception of their psoriasis severity and the Dermatology Life Quality Index (DLQI). Adverse events were systematically recorded. Haematological and biochemical monitoring was performed. Twenty-two patients with psoriasis were recruited. Age, sex and weekly MTX doses were similar in both groups. All 22 patients completed the study. The mean PASI in the FA group increased from 6.4 at baseline to 10.8 at 12 weeks. In the placebo group the mean PASI fell from 9.8 at baseline to 9.2 at 12 weeks. The mean change from baseline in the FA group was 4.4 vs. -0.6 in the placebo group (P < 0.05). Similar trends were observed in the changes in VAS and in the DLQI and differences between the groups were significant for both these parameters (P < 0.05). Few adverse effects were reported. This study suggests that supplementation with FA during long-term MTX treatment reduces the efficacy of MTX in the control of psoriasis. Due to the relatively small sample size and short duration of this study, no conclusions can be drawn regarding the possibility that FA may reduce the side-effects of MTX.
引用
收藏
页码:1169 / 1174
页数:6
相关论文
共 13 条
[1]  
Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185
[2]  
BERTHJONES J, 2006, IN PRESS BR J DEMATO
[3]   Methotrexate for psoriasis: current European practice. A postal survey [J].
Boffa, MJ .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (02) :196-202
[4]   TREATMENT OF PSORIASIS WITH METHOTREXATE AND FOLINIC ACID [J].
BURKHART, CG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1980, 3 (02) :207-208
[6]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[7]  
HILLS RJ, 1992, ACTA DERM-VENEREOL, V72, P438
[8]  
Ive F A, 1970, Trans St Johns Hosp Dermatol Soc, V56, P45
[9]   The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom [J].
Kirby, B ;
Lyon, CC ;
Griffiths, CEM ;
Chalmers, RJG .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2000, 25 (04) :265-268
[10]   Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis [J].
Mazzotti, E ;
Picardi, A ;
Sampogna, F ;
Sera, F ;
Pasquini, P ;
Abeni, D .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (02) :318-322